Pfizer, Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster
Portfolio Pulse from Vandana Singh
Valneva SE and Pfizer Inc have released positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15. The study showed a robust antibody response in all age groups after a booster dose. The vaccine was well-tolerated with no serious adverse events. Pfizer plans to submit a Biologics License Application to the FDA and a Marketing Authorisation Application to the European Medicines Agency in 2026, subject to positive Phase 3 data.
September 07, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive results for Pfizer's Lyme disease vaccine candidate could boost investor confidence and potentially impact the stock price.
The positive results from the study of Pfizer's Lyme disease vaccine candidate could increase investor confidence in the company's ability to develop effective vaccines, potentially leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Positive results for Valneva's Lyme disease vaccine candidate could boost investor confidence and potentially impact the stock price.
The positive results from the study of Valneva's Lyme disease vaccine candidate could increase investor confidence in the company's ability to develop effective vaccines, potentially leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100